FI68806C - Foerfarande foer framstaellning av nya cis-4-fenyl-1,2,3,4-tetrahydro-1-naftalenderivat anvaendbara som depressionslaekemedel - Google Patents

Foerfarande foer framstaellning av nya cis-4-fenyl-1,2,3,4-tetrahydro-1-naftalenderivat anvaendbara som depressionslaekemedel Download PDF

Info

Publication number
FI68806C
FI68806C FI803398A FI803398A FI68806C FI 68806 C FI68806 C FI 68806C FI 803398 A FI803398 A FI 803398A FI 803398 A FI803398 A FI 803398A FI 68806 C FI68806 C FI 68806C
Authority
FI
Finland
Prior art keywords
cis
formula
tetrahydro
hydrogen
compound
Prior art date
Application number
FI803398A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI68806B (fi
FI803398L (fi
Inventor
Willard Mckowan Welch
Charles Armon Harbert
Billie Kenneth Koe
Allen Richard Kraska
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22221931&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI68806(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI803398L publication Critical patent/FI803398L/fi
Publication of FI68806B publication Critical patent/FI68806B/fi
Application granted granted Critical
Publication of FI68806C publication Critical patent/FI68806C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
    • C07C209/04—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups
    • C07C209/14—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups
    • C07C209/16—Preparation of compounds containing amino groups bound to a carbon skeleton by substitution of functional groups by amino groups by substitution of hydroxy groups or of etherified or esterified hydroxy groups with formation of amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/21—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing rings other than six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/28—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of CHx-moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C07C45/46—Friedel-Crafts reactions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/687—Unsaturated compounds containing a keto groups being part of a ring containing halogen
    • C07C49/697—Unsaturated compounds containing a keto groups being part of a ring containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FI803398A 1979-11-01 1980-10-30 Foerfarande foer framstaellning av nya cis-4-fenyl-1,2,3,4-tetrahydro-1-naftalenderivat anvaendbara som depressionslaekemedel FI68806C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9024079 1979-11-01
US06/090,240 US4536518A (en) 1979-11-01 1979-11-01 Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine

Publications (3)

Publication Number Publication Date
FI803398L FI803398L (fi) 1981-05-02
FI68806B FI68806B (fi) 1985-07-31
FI68806C true FI68806C (fi) 1985-11-11

Family

ID=22221931

Family Applications (1)

Application Number Title Priority Date Filing Date
FI803398A FI68806C (fi) 1979-11-01 1980-10-30 Foerfarande foer framstaellning av nya cis-4-fenyl-1,2,3,4-tetrahydro-1-naftalenderivat anvaendbara som depressionslaekemedel

Country Status (38)

Country Link
US (1) US4536518A (fr)
EP (1) EP0030081B1 (fr)
JP (1) JPS605584B2 (fr)
KR (2) KR840002001B1 (fr)
AT (1) ATE2668T1 (fr)
AU (1) AU517357B2 (fr)
BA (2) BA97150B1 (fr)
BG (1) BG60333B2 (fr)
CA (1) CA1130815A (fr)
CS (4) CS238609B2 (fr)
DD (2) DD155615A5 (fr)
DE (2) DE19775012I2 (fr)
DK (1) DK153390C (fr)
EG (1) EG15527A (fr)
ES (2) ES496443A0 (fr)
FI (1) FI68806C (fr)
GR (1) GR70781B (fr)
HK (1) HK82284A (fr)
HR (2) HRP930199B1 (fr)
HU (1) HU182224B (fr)
IE (1) IE50395B1 (fr)
IL (1) IL61374A (fr)
IN (2) IN159643B (fr)
LU (1) LU88330I2 (fr)
LV (2) LV5456A3 (fr)
MX (1) MX5980E (fr)
MY (1) MY8500326A (fr)
NL (1) NL940018I1 (fr)
NO (2) NO148996C (fr)
NZ (1) NZ195407A (fr)
PH (1) PH17319A (fr)
PT (1) PT72004B (fr)
SG (1) SG56584G (fr)
SI (2) SI8012798A8 (fr)
SU (2) SU1014467A3 (fr)
UA (2) UA6311A1 (fr)
YU (2) YU41951B (fr)
ZA (1) ZA806726B (fr)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4839104A (en) * 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4777288A (en) * 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
FR2623802B1 (fr) * 1987-11-26 1990-05-04 Lucien Laboratoires Derives d'amino-4 trifluoromethyl-1 tetralines. leur preparation et leur application en therapeutique
US4855500A (en) * 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
FR2632633B1 (fr) * 1988-06-08 1991-04-05 Delalande Sa Procede de preparation de 4-aryl-1-tetralones
US4981870A (en) * 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US5130338A (en) * 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) * 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
DE69004529T2 (de) * 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
FR2665443B1 (fr) * 1990-08-03 1992-11-06 Lucien Laboratoires Derives d'amino-4-methyl-1-tetralines, leur preparation et leur application en therapeutique.
US5082970A (en) * 1991-03-06 1992-01-21 Pfizer Inc. Process for recycling amine isomer
GB9114947D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline
GB9114948D0 (en) * 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5196607A (en) * 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US5288916A (en) 1993-03-25 1994-02-22 Bend Research, Inc. Enantiomeric resolution of 4-(3,4-dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenone
ATE159706T1 (de) * 1993-11-30 1997-11-15 Pfizer Verfahren zur herstellung von chiralen tetralonen
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US6455736B1 (en) 1994-12-16 2002-09-24 Uop Llc Process for preparation of pharmaceutically desired sertraline and sertraline analogs
US6410794B1 (en) 1994-12-16 2002-06-25 Uop Llc Process for preparation of pharmaceutically desired chiral tetralone from tetralones
WO1996041633A1 (fr) * 1995-06-08 1996-12-27 Eli Lilly And Company Methodes de traitement des rhumes et des rhinites allergiques
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
DE69607904T2 (de) * 1995-08-16 2000-10-05 Lilly Co Eli Potenzierung von Serotonin-Wirkstoffresponz
US5734083A (en) * 1996-05-17 1998-03-31 Torcan Chemical Ltd. Sertraline polymorph
HU222341B1 (hu) * 1996-12-18 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás sertralin előállítására és az eljárásban alkalmazott intermedier
TW526195B (en) * 1997-06-10 2003-04-01 Novartis Ag Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide and their use
EA002482B1 (ru) * 1997-07-01 2002-06-27 Пфайзер Инк. Соли сертралина и лекарственные формы с длительным высвобождением сертралина
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
US20030133974A1 (en) * 1997-07-01 2003-07-17 Curatolo William John Encapsulated solution dosage forms of sertraline
DE69713353D1 (de) * 1997-12-11 2002-07-18 Torcan Chemical Ltd Sertralin-Polymorph mit verbesserter Wasserlöslichkeit
IN191358B (fr) * 1998-01-16 2003-11-29 Pfizer Prod Inc
WO1999046233A1 (fr) * 1998-03-09 1999-09-16 Sumika Fine Chemicals Co., Ltd. Derives de l'alcool benzylique
ES2217748T3 (es) 1998-03-18 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacin catalitica cis-selectiva de ciclohexilidenaminas.
FR2777000B1 (fr) 1998-04-01 2002-09-27 Catalys Procede de preparation de la sertraline racemique
ATE228119T1 (de) * 1998-04-15 2002-12-15 Pfizer Prod Inc Heterocyclische carboxamide
US6054614A (en) * 1998-04-23 2000-04-25 Ciba Specialty Chemicals Corporation Process for the preparation of tetralone imines for the preparation of active pharmaceutical compounds
HU226424B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing enantiomer mixture for preparation of sertraline
HU226423B1 (en) * 1998-05-05 2008-12-29 Egis Gyogyszergyar Nyrt Process for producing a 1(2h)-naphtalene-1-ylidene derivative
IN182588B (fr) * 1998-05-12 1999-05-08 Sun Pharmaceutical Ind Ltd
DE19830201A1 (de) * 1998-07-07 2000-01-13 Boehringer Ingelheim Pharma Mittel mit antidepressiver Wirkung
GEP20032969B (en) * 1998-10-13 2003-05-27 Pfizer Prod Inc Sertraline Oral Concentrate
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
IL132500A0 (en) 1998-10-29 2001-03-19 Pfizer Prod Inc Stereoselective microbial reduction of a racemic tetralone
AU1031500A (en) * 1998-11-03 2000-05-22 Dandy A/S Sucrose fatty acid esters for use as increased release of active ingredients
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
EP1634865A1 (fr) * 1998-11-27 2006-03-15 Teva Pharmaceutical Industries Ltd Polymorphes de chlorhydrate de Sertraline
US6500987B1 (en) 1998-11-27 2002-12-31 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride polymorphs
ES2255320T3 (es) * 1998-11-27 2006-06-16 Teva Pharmaceutical Industries Ltd. Forma v clorhidrato de sertralina.
ES2245639T3 (es) * 1999-03-01 2006-01-16 Pfizer Inc. Compuestos 1,2,3,4-tetrahidro-1-naftalenamina utiles en terapia.
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
YU32700A (sh) * 1999-06-09 2002-03-18 Pfizer Products Inc. Postupak za dobijanje sertralina iz hiralnog tetralona
ES2216923T3 (es) * 1999-07-29 2004-11-01 Ciba Specialty Chemicals Holding Inc. Procedimiento para la hidrogenacion catalitica cis-selectiva de ciclohexilidenaminas.
US6495721B1 (en) * 1999-08-09 2002-12-17 Teva Pharmaceutical Industries Ltd. Sertraline hydrochloride Form II and methods for the preparation thereof
IN185109B (fr) * 1999-09-01 2000-11-18 Torrent Pharmaceuticals Ltd
DK174219B1 (da) * 1999-10-27 2002-09-30 Gea Farmaceutisk Fabrik As Forbedret syntese af racemisk sertralin
US20050119351A1 (en) * 1999-10-29 2005-06-02 Van Der Schaaf Paul A. Polymorphic forms of sertraline hydrochloride
US7442838B2 (en) * 1999-10-29 2008-10-28 Ciba Specialty Chemicals Corp. Polymorphic forms of sertraline hydrochloride
TWI260315B (en) * 1999-10-29 2006-08-21 Ciba Sc Holding Ag Polymorphic forms of sertraline hydrochloride
CN1246298C (zh) 1999-11-16 2006-03-22 西巴特殊化学品控股有限公司 制备酮亚胺的方法
WO2001036377A1 (fr) * 1999-11-16 2001-05-25 Ciba Specialty Chemicals Holding Inc. Procede de preparation de cetimines
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
EP1248605B1 (fr) * 1999-12-21 2007-02-21 Teva Pharmaceutical Industries Ltd. Nouveaux polymorphes de chlorhydrate de sertraline, procedes de preparation correspondants, compositions contenant lesdits polymorphes et methodes d'utilisation correspondantes
AU1724301A (en) 1999-12-23 2001-07-09 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
IN187170B (fr) 2000-01-04 2002-02-23 Sun Pharmaceutical Ind Ltd
CN1232481C (zh) * 2000-03-14 2005-12-21 特瓦制药工业有限公司 制备(+)－顺－舍曲林的方法
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
IN192343B (fr) * 2000-05-26 2004-04-10 Ranbaxy Lab Ltd
ATE324365T1 (de) * 2000-08-31 2006-05-15 Pfizer Phenoxyphenylheterozyklen als serotonin- wiederaufnahmehemmer
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US6482440B2 (en) 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US7067700B2 (en) * 2001-05-31 2006-06-27 Fermion Oy Process for preparing sertraline hydrochloride polymorphic form II
CA2448499A1 (fr) * 2001-06-15 2002-12-27 Orion Corporation Fermion Nouveau procede pour la preparation de (is-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtalenamine
US6723878B2 (en) 2001-06-15 2004-04-20 Orion Corporation Fermion Method for preparing sertraline
AU2002342045C1 (en) * 2001-10-12 2009-07-30 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin Vla antagonists
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
US6897340B2 (en) * 2002-04-29 2005-05-24 Teva Pharmaceutical Industries Ltd. Processes for preparation of polymorphic form II of sertraline hydrochloride
AU2003254475A1 (en) * 2002-07-29 2004-02-16 Cipla Limited Sertraline
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
WO2004071431A2 (fr) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Composition et methode de traitement de troubles neurodegeneratifs
WO2004087732A2 (fr) * 2003-03-11 2004-10-14 Sun Pharmaceutical Industries Limited Procede de preparation de (1s, 4s)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-naphtylamine
TW200503991A (en) * 2003-04-14 2005-02-01 Teva Pharma Hydrogenation of imine intermediates of sertraline with catalysts
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
US20050070577A1 (en) * 2003-07-03 2005-03-31 Pfizer Inc. Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
EP1648854A1 (fr) * 2003-07-15 2006-04-26 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Procedes de preparation de polymorphes de chlorhydrate de sertraline
EP1646605A1 (fr) * 2003-07-15 2006-04-19 Recordati Industria Chimica e Farmaceutica S.p.A. Chlorhydrate de sertraline de forme ii et procedes de preparation associes
HU227495B1 (en) * 2003-07-21 2011-07-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process for producing of imine intermediate
CA2537804A1 (fr) * 2003-09-05 2005-03-17 Teva Pharmaceutical Industries Ltd Procede de recyclage pour l'elaboration de sertraline
EP1663398B1 (fr) 2003-09-12 2009-11-25 Pfizer Limited Associations comprenant des ligands alpha-2-delta et des inhibiteurs du recaptage de la serotonine et de la noradrenaline
BRPI0414347A (pt) * 2003-09-12 2006-11-07 Warner Lambert Co associação compreendendo um ligando de alfa-2-delta e um ssri e/ou snri para tratamento de depressão e distúrbios da ansiedade
AU2004283196B2 (en) * 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
DE602004027401D1 (de) * 2003-11-04 2010-07-08 Cipla Ltd Verfahren zur herstellung von polymorphen von sertralin hydrochlorid
WO2005051919A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
WO2005051488A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Association d'agonistes de la dopamine et d'inhibiteurs de recaptage de la monoamine
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1737473A4 (fr) * 2004-04-19 2009-08-26 Noven Therapeutics Llc Combinaisons de lithium et utilisations associees
JP2007536228A (ja) * 2004-05-06 2007-12-13 サイデックス・インコーポレイテッド セルトラリンおよびスルホアルキルエーテルシクロデキストリンを含有するテイストマスク製剤
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006020850A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
WO2006020853A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2006020852A2 (fr) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Composition pharmaceutique et technique de traitement de troubles neurodegeneratifs
US7345201B2 (en) * 2005-02-23 2008-03-18 Teva Pharmaceutical Industries, Ltd. Processes for preparing sertraline
JP2008534504A (ja) 2005-03-22 2008-08-28 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 月経前障害を治療するためのβラクタミルアルカン酸
JP2006265169A (ja) * 2005-03-24 2006-10-05 Tokuyama Corp アルキリデンコハク酸化合物の製造方法
GB0507090D0 (en) * 2005-04-07 2005-05-11 Sandoz Ag Process for preparing polymorphic form ll of sertraline hydrochloride
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2604759A1 (fr) * 2005-04-22 2006-11-02 Wyeth Derives de dihydrobenzofurane et utilisations de ceux-ci
AR055054A1 (es) * 2005-04-22 2007-08-01 Wyeth Corp Cristales formados de clorhidrato de (((2r)-7-(2,6-diclorofenil)-5-fluoro-2,3- dihidro-1-benzofurano-2-il) metil ) amina
WO2006116151A1 (fr) 2005-04-22 2006-11-02 Wyeth Derives d’alcanamine de benzofuranyle et leurs utilisations comme agonistes 5-ht2c
JP2008538572A (ja) 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
AU2006239937A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
CA2576097C (fr) * 2005-06-03 2009-10-27 Hetero Drugs Limited Synthese hautement stereoselective de sertraline
WO2007008317A2 (fr) * 2005-06-09 2007-01-18 Teva Pharmaceutical Industries Ltd. Procede de preparation de la forme i de chlorhydrate de sertraline
WO2007002597A2 (fr) * 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Formulations a liberation modifiee d'un sel de bupropion
EP1904843A2 (fr) 2005-07-08 2008-04-02 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
ES2726942T3 (es) 2005-07-19 2019-10-10 Azevan Pharmaceuticals Inc Antagonista de vasopresina de tipo beta-lactamil fenilalanina, cisteína y serina
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
EP2377530A3 (fr) 2005-10-21 2012-06-20 Braincells, Inc. Modulation de neurogénèse par inhibition PDE
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CA2636275C (fr) * 2006-01-06 2013-02-12 Sepracor Inc. Inhibiteurs de recaptage de monoamine a base de tetralone
EP1858838A1 (fr) * 2006-01-23 2007-11-28 Teva Pharmaceutical Industries Ltd. Procede de recyclage pour preparer la sertraline
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
WO2007119247A2 (fr) * 2006-04-17 2007-10-25 Unichem Laboratories Limited Procédé de production amélioré destiné à la préparation de la forme polymorphe ii de l'hydrochlorure de cis-(1s)-n-methyl-4-(3,4-dichlorophényle)-1,2,3,4-tétrahydro-1-napthlèneamine (hydrochlorure de sertraline)
TR200808115T1 (tr) * 2006-04-28 2009-03-23 Sandoz Ag 4(S,R)-(3,4-diklorofenil)-3,4-dihidro-l(2H)-naftalin-l-ilid n]metilamin'ın Hazırlanması için Proses.@
EP2382975A3 (fr) 2006-05-09 2012-02-29 Braincells, Inc. Neurogénèse par modulation d'angiotensine
WO2007134077A2 (fr) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenèse induite par le récepteur 5ht
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7518019B2 (en) 2006-06-01 2009-04-14 Hetero Drugs Limited Processes for preparing sertraline hydrochloride crystalline forms
US20100279990A1 (en) * 2006-06-13 2010-11-04 Ramot At Tel-Aviv University Ltd. Antiproliferative compounds, compositions and methods of use
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US20080033045A1 (en) * 2006-07-07 2008-02-07 Myriad Genetics, Incorporated Treatment of psychiatric disorders
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
BRPI0716604A2 (pt) 2006-09-08 2013-04-09 Braincells Inc combinaÇÕes contendo um derivado de 4-acilaminopiridina
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
FR2909376A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
WO2008086483A2 (fr) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation de la neurogenèse en utilisant du modafinil
CA2594198A1 (fr) * 2007-07-20 2009-01-20 Apotex Pharmachem Inc. Procede inedit de preparation d'hydrochlorure de sertraline de forme ii
US20090062399A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched sertraline
EP2291181B9 (fr) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Utilisation de la captodiamine pour le traitement des symptômes de la dépression
EP2288345B1 (fr) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Produits psycho-pharmaceutiques
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
US9260413B2 (en) * 2010-03-04 2016-02-16 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
EP2380595A1 (fr) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions et procédés pour la fourniture sélective de molécules d'oligonucléotides à des types de neurones spécifiques
US8440655B2 (en) 2010-06-21 2013-05-14 Theracos, Inc. Combination therapy for the treatment of diabetes
ES2662350T3 (es) 2010-07-01 2018-04-06 Azevan Pharmaceuticals, Inc. Procedimientos para el tratamiento del trastorno por estrés postraumático
JP2014508187A (ja) 2011-03-17 2014-04-03 ルピン・リミテッド 選択的セロトニン再取り込み阻害薬の放出制御医薬組成物
KR101340270B1 (ko) * 2011-11-10 2013-12-10 보령제약 주식회사 (+)-시스-서트랄린의 선택적인 제조방법
SG11201500729SA (en) * 2012-10-18 2015-06-29 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
BR112016022575A2 (pt) 2014-03-28 2017-08-15 Azevan Pharmaceuticals Inc Composições e métodos para o tratamento de doenças neurodegenerativas
WO2015193921A1 (fr) 2014-06-20 2015-12-23 Council Of Scientific And Industrial Research Synthèse asymétrique organocatalytique d'antidépresseurs
WO2016023831A1 (fr) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Dérivés de pyrrolo[3,2-d]pyrimidine-2,4(3h,5h)-dione
EP3180340B1 (fr) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
EP3180345B1 (fr) * 2014-08-11 2018-10-10 Hydra Biosciences, Inc. Dérivés thieno- et furo[2,3-d]pyrimidine-2,4[1h,3h]-dione en tant que modulateurs trpc5 pour le traitement de maladies neuropsychiatriques
JP6695323B2 (ja) * 2014-08-11 2020-05-20 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピリド［３，４−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体
CN108290171B (zh) 2015-09-21 2022-07-01 约翰逊父子公司 用于混合及分配的系统
CN111295373A (zh) 2017-09-15 2020-06-16 阿泽凡药物公司 用于治疗脑损伤的组合物和方法
WO2020043716A1 (fr) 2018-08-27 2020-03-05 Katholieke Universiteit Leuven Ciblage pharmacologique de la synthèse de novo de sérine/glycine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887509A (en) * 1956-11-05 1959-05-19 Lilly Co Eli Hydroxybenzoyl benzoate salt of beta-(o-chlorophenyl)-beta-hydroxyethyl isopropylamine
US3704323A (en) * 1969-12-23 1972-11-28 Squibb & Sons Inc Indane derivatives
US4045488A (en) * 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
US4029731A (en) * 1974-11-06 1977-06-14 Pfizer Inc. Aminophenyltetralin compounds

Also Published As

Publication number Publication date
CA1130815A (fr) 1982-08-31
YU279880A (en) 1983-09-30
DK395280A (da) 1981-05-02
DE3062225D1 (en) 1983-04-07
DK153390C (da) 1988-12-05
IN159643B (fr) 1987-05-30
SI8012798A8 (sl) 1994-12-31
DD155615A5 (de) 1982-06-23
CS238618B2 (en) 1985-12-16
ES8201949A1 (es) 1982-01-16
DD203045A5 (de) 1983-10-12
US4536518A (en) 1985-08-20
GR70781B (fr) 1983-03-23
FI68806B (fi) 1985-07-31
NZ195407A (en) 1984-05-31
PT72004A (en) 1980-11-01
BG60333B2 (bg) 1994-11-30
KR830004202A (ko) 1983-07-06
YU41951B (en) 1988-02-29
DE19775012I2 (de) 2001-02-08
HK82284A (en) 1984-11-09
FI803398L (fi) 1981-05-02
IN159644B (fr) 1987-05-30
KR840002000B1 (ko) 1984-10-27
HRP931527B1 (en) 1996-04-30
AU6389780A (en) 1981-05-07
UA6301A1 (uk) 1994-12-29
JPS605584B2 (ja) 1985-02-12
ATE2668T1 (de) 1986-03-15
EP0030081A1 (fr) 1981-06-10
CS238617B2 (en) 1985-12-16
PT72004B (en) 1981-08-31
HU182224B (en) 1983-12-28
SU1034602A3 (ru) 1983-08-07
ZA806726B (en) 1981-10-28
LV5456A3 (lv) 1994-03-10
NO148996B (no) 1983-10-17
BA97149B1 (bs) 1998-12-28
LV5457A3 (lv) 1994-03-10
MX5980E (es) 1984-09-12
NO148996C (no) 1984-01-25
BA97150B1 (bs) 1998-12-28
ES8207123A1 (es) 1982-09-01
AU517357B2 (en) 1981-07-23
PH17319A (en) 1984-07-20
KR840002001B1 (ko) 1984-10-27
CS354291A3 (en) 1992-12-16
HRP930199B1 (en) 1996-02-29
NL940018I1 (nl) 1994-10-17
YU42846B (en) 1988-12-31
SU1014467A3 (ru) 1983-04-23
UA6311A1 (uk) 1994-12-29
JPS5686137A (en) 1981-07-13
ES506892A0 (es) 1982-09-01
IE802259L (en) 1981-05-01
NO1996011I1 (no) 1996-09-24
CS238609B2 (en) 1985-12-16
EP0030081B1 (fr) 1983-03-02
ES496443A0 (es) 1982-01-16
SI8310672A8 (en) 1996-04-30
EG15527A (en) 1987-04-30
NO803258L (no) 1981-05-04
IL61374A (en) 1983-10-31
IE50395B1 (en) 1986-04-16
YU67283A (en) 1983-10-31
DK153390B (da) 1988-07-11
MY8500326A (en) 1985-12-31
SG56584G (en) 1985-03-08
IL61374A0 (en) 1980-12-31
LU88330I2 (fr) 1994-05-04

Similar Documents

Publication Publication Date Title
FI68806C (fi) Foerfarande foer framstaellning av nya cis-4-fenyl-1,2,3,4-tetrahydro-1-naftalenderivat anvaendbara som depressionslaekemedel
FI68807C (fi) Foerfarande foer framstaellning av nya som depressionslaekemedel anvaendbara trans-4-fenyl-1,2,3,4-tetrahydro-1-naftalenaminderivat
KR100446893B1 (ko) Ｃｎｓ 장해 치료용 모노아민 재흡수 억제제
Welch et al. Nontricyclic antidepressant agents derived from cis-and trans-1-amino-4-aryltetralins
US3637740A (en) Aminobenzocycloalkane compounds
NZ194714A (en) Propenylamine derivatives and pharmaceutical compositions
US6127424A (en) Aryl-substituted cyclobutylalkylamines for treating obesity
RU2232753C2 (ru) 4-замещенные пиперидины, фармацевтическая композиция на их основе и способ лечения заболеваний центральной нервной системы
KR840002020B1 (ko) 트랜스-4-페닐-1, 2, 3, 4-테트라하이드로-1-나프탈렌아민 유도체의 제조방법
EP0000322B1 (fr) Composés avec une activité antidépressive et tranquillisante, compositions pharmaceutiques les contenant; procédés et intermédiaires pour leur préparation.
US4705807A (en) Amine derivatives
Geyer III et al. (.+-.)-4-Aryl-4, 5-dihydro-3H-1, 3-benzodiazepines. 1. Synthesis and evaluation of (.+-.)-4, 5-dihydro-2, 3-dimethyl-4-phenyl-3H-1, 3-benzodiazepine and analogs as potential antidepressant agents
FI58326B (fi) Foerfarande foer framstaellning av som beta-adrenergiskt stimulerande medel anvaendbara alfa-aminometyl-4-hydroxi-3-metylsulfonyl-metylbensylalkoholer
NZ227299A (en) Hydroxy- or keto-amine derivatives and pharmaceutical compositions
PL129248B1 (en) Method of preparation of novel cis isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtaleneamine
EP1073645A2 (fr) Procede de preparation d'imines de tetralone dans la fabrication de composes pharmaceutiques actifs
PL130600B1 (en) Process for preparing novel cis-isomer derivatives of 4-phenyl-1,2,3,4-tetrahydro-1-naphtalenamine

Legal Events

Date Code Title Description
ND Supplementary protection certificate (spc) granted
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L35

Extension date: 20051030

MA Patent expired

Owner name: PFIZER INC.